Citations

Clear

4207 citation(s) found for "Chen, Yu".

Multivariate zero-inflated generalised poisson data generation methods for simulating counts of adverse events
Chen, Ruizhe , Shi, Qian , Demirtas, Hakan , Shi, Qian , Chen, Ruizhe , Demirtas, Hakan

Mayo Clinic

Journal of Statistical Computation and Simulation | November 17, 2025 | Volume: 96 | Issue: 6 | Pages: 1359-1389

10.1080/00949655.2025.2588606 Get It

A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma
Landry, Alexander , Wang, Justin Z. , Patil, Vikas, Ajisebutu, Andrew, Gui, Chloe , Yefet, Leeor, Mamatjan, Yasin , Wei, Qingxia , Singh, Olivia, Mansouri, Sheila , Ehret, Felix , Capper, David , Cohen-Gadol, Aaron A, Behling, Felix , Sloan, Andrew E. , Chambless, Lola B. , Makarenko, Serge , Yip, Stephen , Tsang, Derek S. , Gao, Andrew , Aldape, Kenneth , Nassiri, Farshad , Zadeh, Gelareh , Santarius, Thomas , Selman, Warren R., Couce, Marta , Wen, Patrick Y. , Walbert, Tobias , Felicella, Michelle M. , Brodie, Chaya , Snyder, James P., Saladino, Andrea , Schichor, Christian , Tonn, Jörg‐Christian, Goldbrunner, Roland , Timmer, Marco , Schimdt, Nils Ole, Jenkinson, Michael D. , Millward, Christopher P. , Islim, Abdurrahman I. , Fl, Behling, Santacroce, Antonio , Schittenhelm, Jens , Raleigh, David R. , Butowski, Nicholas , Westphal, Manfred , Lamszus, Katrin , Mawrin, Christian , Kurz, Sylvia C. , Zada, Gabriel , Yip, Stephen, Zherebitskiy, Viktor, Hnenny, Luke, Dunn, Ian F. , Moliterno, Jennifer , McDermott, Michael , Vogelbaum, Michael A. , Aldape, Kenneth, Alkividias, Tzannis, Short, Susan , Bos, Eelke M. , Dincer, Alper , Paßlack, Peter, Ehret, Felix, Lopez, Clara, Arvaniti, Christina , Benjamin, Carolina , Jackson, Christina , Jeyaretna, Sanjeeva, Scartoni, Daniele , Amelio, Dante , Ivanidze, Jana , Kien, Duong Trung, Millareschavez, Miguel, AlThgafi, Malak, LeRhun, Emilie, Smee, Robert, Muirhead, William , Molina, Eric Suero, Julius, Vitowanu, Chen, J., Mrugała, Maciej M. , Castro, Ana Valeria , Mamatjan, Yasin , Capper, David , Tatagiba, Marcos , Barnholtz-Sloan, Jill S , Yip, Stephen , Aldape, Kenneth , Zadeh, Gelareh , Short, Susan C , Yefet, Leeor S. , Ellenbogen, Yosef , Liu, Jeff , Singh, Olivia , Tabatabai, Ghazaleh , Tatagiba, Marcos , Barnholtz‐Sloan, Jill S. , Mansouri, Alireza , Brastianos, Priscilla K. , Shih, Helen A. , Bi, Wenya Linda , Huang, Raymond Y. , Wen, Patrick Yung , Lee, Ian , Malta, Tathiane Maistro , Castro, Ana Valéria , Noushmehr, Houtan , DiMeco, Francesco , Pollo, Bianca , Kaufmann, Timothy J. , Lachance, Daniel Honore , Giannini, Caterina , Galanis, Evanthia , Raghunathan, Aditya , Hanemann, C. Oliver , Au, Karolyn , Galldiks, Norbert , Herold‐Mende, Christel C. , Sahm, Felix , Jungk, Christine , Jungwirth, Gerhard , Deimling, Andreas von , Drummond, Katharine Jann , Morokoff, Andrew P. , Renovanz, Mirjam , Fougère, Christian la , Perry, Arie , Ricklefs, Franz , Horbinski, Craig , Ng, Ho‐Keung , Snuderl, Matija , Sulman, Erik P. , Cohen‐Gadol, Aaron , Javadpour, Mohsen , Fountain, Daniel Mark , Mathiesen, Tiit Illimar , Pathmanaban, Omar Nathan , Boutros, Paul C. , Fountas, Konstantinos N. , Walsh, Kyle M. , Carvalho, Bruno , Maas, Sybren L. N. , Deng, Maximilian Y. , Mehta, Minesh P. , Odia, Yazmín , Everson, Richard G. , Balogun, James , Calabrese, Evan , Karschnia, Philipp , Teske, Nico , Fariselli, Laura , Greve, Tobias , Ivan, Michael E , Palmer, Joshua D. , Ostrom, Quinn T. , Youngblood, Mark W. , Emerson, Sam, Weller, Michael , Martínez-Pérez, Rafael , Mukherjee, Raj, Cervio, Andrés , Turner, Clinton P. , Chen, Jiawei, Karmur, Brij S. , Neth, Bryan J.

Mayo Clinic

Neuro-Oncology | November 15, 2025 | Volume: 28 | Issue: 2 | Pages: 430-439

10.1093/neuonc/noaf237 | PMID 41259653 Get It

Abstract Background DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patients. To allow for seamless integration of these complementary models into clinical practice, a practical framework is needed. Methods We leveraged a cohort of nearly 2000 surgically-treated meningiomas with DNA methylation profiling and clinical outcomes data. Existing methylation-based prediction models were dichotomized to yield four risk groups: low and high recurrent risk, each with RT sensitive and resistant subgroups. Risk groups were correlated with progression-free survival in the context of existing biomarkers including extent of resection and WHO grade. Results We first demonstrated that all risk groups benefit from gross total resection. All “high-risk, RT sensitive” tumors (n = 306, 15.7%) also benefited from adjuvant RT: after GTR, median PFS increased from 4.68 (4.13-9.48) years to not reached (P = .003); after subtotal resection (STR), from 2.12 (1.59-3.02) to 4.09 (3.41-not reached) years (P = .004). “Low-risk, RT sensitive cases” (n = 1207, 61.8%) also benefited from RT after STR (median PFS 7.39 (6.66-12.8) vs. 16.53 (10.35-not reached) years, P = .03), suggesting that RT be considered in these patients. Neither “low-risk RT resistant” (n = 84, 4.3%) nor “high-risk RT resistant” (n = 356, 18.2%) cases benefited from RT, and the latter group was associated with universally poor outcomes. Conclusions We identify methylation-defined risk groups of meningioma for which additional benefit is gained from adjuvant RT, leading to a clinical decision-making framework for straightforward integration of molecular models into clinical practice.
Transcriptional readthrough at Atf4 locus suppresses Rps19bp1 and impairs heart development
Wu, Tongbin , Chen, Zeyu , Chen, Danni , Liang, Zhengyu , Barroga, Fhujjen, Evans, Sylvia Μ. , Chen, Ju , Chen, Zeyu , Adams, Christopher , Chen, Ju , Zhang, Zengming, Adams, Christopher M. , Gu, Yusu , Ye, Mao , Zhou, Xiaohai

Mayo Clinic

Cardiovascular Research | November 14, 2025 | Volume: 121 | Issue: 18 | Pages: 2909-2921

10.1093/cvr/cvaf237 | PMID 41248983 Get It

Abstract Aims Activating transcription factor 4 (ATF4) functions as a transcriptional regulator in various cell types and tissues under both physiological and pathological conditions. While previous studies have linked ATF4 activation with promoting cardiomyocyte (CM) death in dilated cardiomyopathy (DCM), atrial fibrillation, and heart failure, its role in developing CMs remains unexplored. Methods and results We generated multiple distinct CM-specific (Atf4cKO(e2/3/pA) and Atf4cKO(e2)) and global Atf4 knockout (KO; Atf47del/7del and Atf41ins/1ins) mouse models targeting different Atf4 regions, as well as CM-specific deletion of Rps19bp1 to study cardiac phenotypes. Detailed morphological and molecular analyses were performed. Atf4cKO(e2/3/pA) [targeting exon 2–3 including the polyadenylation signal (polyA)] mice exhibited severe cardiac defects and died before E17.5, likely due to ectopic activation of the p53 signaling pathway resulting from Rps19bp1 downregulation, a potent suppressor of p53. Further investigation revealed that deleting the polyA signal of Atf4 in Atf4cKO(e2/3/pA) mice led to transcriptional readthrough, resulting in the formation of an Atf4-Cacna1i fusion transcript and Rps19bp1 downregulation. To avoid readthrough while abolishing ATF4 function, we introduced small indels into exon 3 of Atf4 in mice (Atf47del/7del and Atf41ins/1ins), which showed normal Rps19bp1 expression and cardiac morphology. Importantly, CM-specific deletion of Rps19bp1 recapitulated the cardiac defects and transcriptional change seen in Atf4cKO(e2/3/pA) mice. Conclusion We found that the downregulation of Rps19bp1, not the loss of ATF4 function, underlies the cardiac phenotypes in Atf4cKO(e2/3/pA) mice. The reduced expression of Rps19bp1 in Atf4cKO(e2/3/pA) mice is likely due to the unintentional deletion of Atf4 polyA signal and subsequent transcriptional readthrough, underscoring the essential role of RPS19BP1, not ATF4, in cardiac development. Consistent Rps19bp1 downregulation has been observed in other tissue-specific Atf4 KO models utilizing the Atf4fl(e2/3/pA) allele, suggesting that previously reported Atf4 KO phenotypes may result from Atf4 transcriptional readthrough effects. These findings reveal a locus-dependent transcriptional interference mechanism and emphasize the importance of avoiding confounding cis effects in genetically engineered models.
Associations of lifestyle factors with amyloid pathology in persons without dementia
Oomens, Julie Elisabeth , Vos, Stephanie J. B. , Maserejian, Nancy N., Didic, Mira , Engelborghs, Sebastiaan , Fladby, Tormod, Fröhlich, Lutz, Gill, Kiran Dip, Grimmer, Timo, Itoh, Yoshiaki , Landau, Susan, Lleó, Alberto, Meyer, Philipp T. , Pardini, Matteo , Rami, Lorena , Reiman, Eric M. , Rinne, Juha O. , Sánchez‐Juan, Pascual, Scarmeas, Nikolaos , Villeneuve, Sylvia , Waldemar, Gunhild , Alcolea, Daniel, Altomare, Daniele , Baldeiras, Inês , Blennow, Kaj , Cerman, Jiří , Chipi, Elena , Day, Gregory S. , Förster, Stefan , Frings, Lars , Guedj, Éric , Habeck, Christian , Hausner, Lucrezia , Jiménez‐Bonilla, J., Juaristi, Arantxa, Kern, Silke , Kirsebom, Bjørn‐Eivind , Legdeur, Nienke , Xiong, Chengjie , Maier, W., Marquié, Marta, Minatani, Shinobu, Prabhakar, Sudesh, Ramakers, Inez H.G.B. , Rodríguez‐Rodríguez, Eloy , Ruiz, Agustín, Rüther, E., Sakhardande, Jayant, Selnes, Per, Spiru, Luiza , Vermunt, Lisa , Wallin, Åsa K., Zettergren, Anna , (ADNI), for the Alzheimer's Disease Neuroimaging Initiative, group, A4 Study, (DIAN), Dominantly Inherited Alzheimer Network, (KBASE), Japan Alzheimer's Disease Neuroimaging Initiative (J-ADNI), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease, Ossenkoppele, Rik, Verhey, Frans RJ, Visser, Pieter Jelle, Jansen, Willemijn J, Marquié, Marta , Selnes, Per , Day, Gregory S , Xiong, Chengjie , Oomens, Julie E , Boada, Merçé , Fladby, Tormod , Flier, Wiesje M. van der , Frisoni, Giovanni B. , Fröhlich, Lutz, Grimmer, Timo , Hort, Jakub , Iwatsubo, Takeshi , Klimkowicz‐Mrowiec, Aleksandra , Lee, Dong Young , Lleó, Alberto , Martínez‐Lage, Pablo , Mendonça, Alexandre de , Parchi, Piero , Parnetti, Lucilla , Popp, Julius , Rodrigue, Karen M. , Santana, Isabel , Scheltens, Philip , Skoog, Ingmar , Sperling, Reisa Anne , Stern, Yaakov , Wiltfang, Jens , Zetterberg, Henrik , Alcolea, Daniel , Allegri, Ricardo , Bateman, Randall J. , Baiardi, Simone , Braber, Anouk den , Buchem, Mark A. van , Byun, Min Soo , Chen, Kewei , Drzezga, Alexander E. , Ekblad, Laura L. , Fortea, Juan , Freund‐Levi, Yvonne , Handels, Ron , Hellwig, Sabine , Kandimalla, Ramesh , Kornhuber, Johannes , Morbelli, Silvia , Mroczko, Barbara , Ntanasi, Eva , Oliveira, Catarina Resende , Orellana, Adelina , Peters, Oliver , Ruiz, Agustı́n , Silva, Dina , Soininen, Hilkka S. , Takeda, Akitoshi , Teunissen, Charlotte E. , Tijms, Betty M. , Wiels, Wietse A. , Yannakoulia, Mary , Yi, Dahyun , (ADNI), for the Alzheimer's Disease Neuroimaging Initiative, group, A4 Study, (DIAN), Dominantly Inherited Alzheimer Network, (KBASE), Japan Alzheimer's Disease Neuroimaging Initiative (J-ADNI), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease, Ossenkoppele, Rik, Verhey, Frans R.J. , Visser, Pieter Jelle , Jansen, Willemijn J.

Mayo Clinic

Journal of Alzheimer’s Disease | November 14, 2025 | Volume: 108 | Issue: 3 | Pages: 1043-1059

10.1177/13872877251379083 | PMID 41234025 Get It

Background The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective The aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity with cerebral amyloid pathology. Methods For this cross-sectional study, we selected participants from the Amyloid Biomarker Study data pooling initiative. We used generalized estimating equations to assess associations of dichotomized lifestyle measures with amyloid pathology. Results We included 9171 participants with normal cognition (NC) and 2555 participants with mild cognitive impairment (MCI) from the Amyloid Biomarker Study. Of participants with NC, 58% were women, 34% were APOE ε4 carrier, and 27% had amyloid pathology. Of participants with MCI, 48% were women, 47% were APOE ε4 carrier, and 57% had amyloid pathology. In NC, cognitively active participants were less likely to have amyloid pathology (OR = 0.77, 95%CI 0.66–0.89, p < 0.001). In MCI, participants who had ever smoked or had sleep problems were less likely to have amyloid pathology (OR = 0.85, 95%CI 0.73–0.99, p = 0.029; OR = 0.62, 95%CI 0.45–0.86, p = 0.004). Conclusions In NC, cognitive activity was associated with a lower frequency of amyloid pathology. In MCI, favorable lifestyle behaviors were not associated with a lower frequency of amyloid pathology. The results of the current study contribute to the broader evidence base on lifestyle and AD by further characterizing the role of lifestyle behaviors in AD pathology across different clinical stages.
Transformable Renal Cancer Targeted Responsive Nanopeptide Probes Effectively Inhibit Renal Cancer Progression and Metastasis by Inhibiting Renal Blood Vessels and Cancer Cells
Kong, Bin , Wu, Xiu‐Hai, Li, Cong , Chen, Meiqun, Liu, Yuwen , Liu, Cunyao, Wang, Xinyue , Chen, Bogong, Zang, Jiahui, Jian, Lingrui, Shen, Jiachen , Yu, Jiaao, Wu, Qiang , Yang, Guang , Wang, Ziqi , Wang, Lu , Wang, Lu , Liu, Pan , Chen, Meiqun, Liu, Cunyao, Liu, Ming

Mayo Clinic

ACS Applied Materials & Interfaces | November 13, 2025 | Volume: 17 | Issue: 47 | Pages: 64232-64243

10.1021/acsami.5c16546 | PMID 41231680 Get It

Quality of life and healthcare resource utilization among adult patients with short bowel syndrome: A mixed‐methods study leveraging an integrated database
Kuk, Deborah , Gower, Megan, Kirby, Michelle, Terreri, Brian , Feldman, Josh , Mundi, Manpreet S. , Feldman, Josh , Mundi, Manpreet S , Chen, Brian , McCue, Maggie

Mayo Clinic

Nutrition in Clinical Practice | November 11, 2025 | Volume: 41 | Issue: 4 | Pages: 1096-1105

10.1002/ncp.70059 | PMID 41215658 Get It

Abstract Background Short bowel syndrome (SBS) is a chronic condition requiring parenteral nutrition (PN) support and multidisciplinary management. However, disparities in access to care and standardized treatment pathways, in addition to economic burden, remain considerable for patients. Understanding healthcare resource utilization (HCRU) and treatment patterns, especially in relation to patient‐reported outcomes (PROs), is critical for improving care. Methods A cross‐sectional, multiphase study was conducted in 2023. This analysis focuses on phase 3, using a deidentified database that integrated claims and PROs from 68 patients in phase 2. Twenty‐three patients were included in the analytic cohort after applying additional criteria. Descriptive statistics summarized patient demographics, HCRU, and treatment patterns for the overall cohort and stratified by median SBS–quality of life (QoL) score. Results The median age at SBS diagnosis was 35 years, and 91% of patients were female. Patients saw a median of 35 different healthcare providers and underwent approximately five procedures before diagnosis. In the 6 months after diagnosis, 39% had been hospitalized, and 26% had emergency room (ER) visits. Healthcare costs increased after diagnosis, with long‐term PN use accounting for 34% of total costs. Patients with worse QoL had a higher number of ER visits than patients with better QoL. Patients who self‐reported being treated by SBS specialists had lower healthcare costs than patients who did not receive specialized care. Conclusion SBS is associated with high HCRU and costs, particularly for patients with poor QoL. Multidisciplinary care, especially from SBS specialists, may help reduce healthcare costs and improve patient outcomes.
TIP-26. A phase II study evaluating the safety, efficacy, and intracranial activity of tarlatamab in recurrent/refractory IDH -mutant gliomas (TARGID)
Wang, Xin , Bennett, Julie, Muniz, Thiago Pimentel , Fat, Mary Jane Lim, Gao, Andrew , Zadeh, Gelareh , Nassiri, Farshad , Chen, Eric X. , Mason, Warren , Bennett, Julie , Tsang, Derek S.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v426-v427

10.1093/neuonc/noaf201.1686 Get It

Abstract Recurrent or refractory IDH-mutant (mt) gliomas represent a population with significant unmet clinical need. The Notch ligand delta-like 3 (DLL3) is a tumor-associated antigen that is highly and homogeneously expressed in IDH-mt gliomas but absent in normal brain tissue, making it an attractive therapeutic target. Tarlatamab is a half-life extended bispecific T-cell engager that targets DLL3 and CD3 to redirect cytotoxic T cells toward DLL3-expressing tumor cells. Given the specific expression of DLL3 in IDH-mt gliomas and promising activity of tarlatamab in other DLL3-positive tumors, this study investigates the safety, efficacy, and intracranial activity of tarlatamab in this patient population. TARGID is an open-label, phase II trial enrolling adult patients with histologically confirmed IDH1 or IDH2-mt astrocytoma or oligodendroglioma following up to two prior lines of systemic therapies. The study comprises two cohorts. Cohort 1 (n=10) includes patients with resectable disease who will receive up to three cycles of tarlatamab prior to surgery; postoperative continuation is permitted. The primary endpoint for this cohort is the change in CD8+ T-cell infiltration in tumor tissue and blood. Cohort 2 (n=34) includes patients with unresectable disease and uses a Simon’s optimal two-stage design (H0: P ≤ 0.1 versus H1: P ≥ 0.25). In the 1st stage, 13 patients will be accrued. If 2 or more responses are observed, 21 additional patients will be enrolled. Tarlatamab is administered intravenously at 10 mg every two weeks, following a 1 mg priming dose on Cycle 1 Day 1. The primary endpoint is objective response rate by RANO 2.0. Exploratory endpoints include DLL3 expression, circulating biomarkers, and immune correlatives. The trial is currently in activation, with first patient enrollment anticipated in Q3 2025. The study is supported by the provision of study drug from Amgen as an investigator-initiated trial.
TMIC-78. Aquaporin-4 loss in astrocytes drives glioblastoma-associated cerebral edema and alters the tumor immune microenvironment
Flick, Matthew J. , Garvin, Kaisha, Vallcorba, Montserrat Puigdelloses, Ramos, Susana Isabel , Tsankova, Nadejda M. , Tran, Nhan L. , Hu, Leland , Heiland, Dieter Henrik , Tran, Nhan L , Joshi, Tanvi , Flick, Matthew J, Garvin, Kaisha, Dedhia, Mehek , Chen, Zhihong , Peters, Katherine B. , Smith, Alexander J. , Hambardzumyan, Dolores

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v462-v463

10.1093/neuonc/noaf201.1833 Get It

Abstract Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a dismal 5-year survival rate of ~6.5%. Vasogenic cerebral edema is a severe complication that occurs in the majority of GBM patients, leading to a significant increase in intracranial pressure, neurological deficits, and increased mortality rates. GBM-associated edema is almost exclusively managed by the corticosteroid dexamethasone, the use of which is associated with immunosuppression and interference with radiation therapy. While there is considerable research on edema formation, little is known about how edema resolution occurs in GBM, particularly in response to dexamethasone or other anti-edema therapies. This gap in understanding highlights the need for new approaches to treat edema effectively. The water channel aquaporin-4 (AQP4), a key player in the brain’s water homeostasis, is upregulated in GBM compared to the normal brain. To investigate the role of AQP4 in GBM-associated edema, we used the RCAS/tv-a system to generate de novo GBM with different driver mutations in Aqp4 knockout (KO) and wild-type (WT) mice. Our results indicated that Aqp4 KO tumor-bearing mice had shortened survival and increased edema content. Additionally, Aqp4 loss decreased astrocyte coverage specifically in the tumor core but not the tumor periphery. Our single cell RNA-seq data suggested that Aqp4 loss led to an astrocytic shift towards a less reactive, progenitor-like state, while also decreasing the myeloid and CD8+ T cell population in the tumor microenvironment. Interestingly, tumor-bearing mice treated with anti-VEGFA antibody, which has anti-edema properties, showed increased expression of Aqp4 and reduced vessel leakage. This suggests that AQP4 plays a critical role in mediating the effects of anti-VEGFA therapy. Overall, this study highlights the important role of AQP4 in the resolution of edema, while also revealing its additional effects on astrocyte activation and the immune microenvironment in GBM.
TMIC-25. SMAC Mimetic Targets Glioblastoma Stem Cells and Reprograms the Associated Tumor Microenvironment
Wu, Qiong , Du, Dongliang , Chen, Jianan , Berglund, Anders , Macaulay, Robert , Etame, Arnold B.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v449-v449

10.1093/neuonc/noaf201.1780 Get It

Abstract Glioblastoma (GBM) is a highly treatment-resistant malignancy characterized by its poor prognosis and intrinsic resistance to therapy, driven largely by glioblastoma stem cells (GSCs) and an immunosuppressive tumor microenvironment (TME). This dual resistance plays a significant role in the failure of current treatment strategies. Consequently, there is an urgent need for novel therapeutic approaches that can effectively target GSCs while simultaneously reshaping the TME to promote anti-tumor immunity. In this study, we investigated the dual therapeutic potential of Xevinapant, a lead SMAC mimetic, through a combination of in vitro, in vivo, and single-cell transcriptomic analyses. We found that Xevinapant demonstrated potent anti-tumor activity through inducing dose-dependent apoptosis and significantly reduced cell viability in both human and mouse GSCs. In vivo administration of Xevinapant led to significant tumor suppression and extended overall survival in orthotopic models. Notably, our single-cell RNA sequencing result revealed that Xevinapant activated immune effector cell responses, contributing to the reprogramming of the immunosuppressive TME. Immune cell activation (both lymphoid and myeloid lineages) was further validated by flow cytometry using tumor-derived cells. To overcome potential therapeutic resistance, we derived Xevinapant-specific gene expression signatures and queried the LINCS database to identify small molecules with synergistic effects. Our analysis identified a promising compound ST-059620 that, when used in combination with Xevinapant, enhanced therapeutic efficacy and overcame resistance. Taken together, our findings highlight the dual mechanism of action of Xevinapant in targeting both tumor-intrinsic and microenvironmental resistance mechanisms. These results support the continued clinical development of Xevinapant and provide a strong rationale for combination strategies aimed at improving treatment efficacy in GBM.